Pain
VIDEO: When it's ‘endometriosis until proven otherwise’
Cyclic pain, particularly in the abdomen, that impacts day-to-day life is not normal. Health care providers should always consider endometriosis as a possibility if patients present with such symptoms.
Autosomal dominant PKD registry may help assess disease burden in patients with CKD
The autosomal dominant polycystic kidney disease registry may help assess various aspects of disease burden on patients’ health-related quality of life, according to published research.
OK-101 improves ocular pain, tear breakup time as early as day 15 in phase 2 DED trial
Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.
VIDEO: Highlights from ACR 2023
In this Healio video, Philip J. Mease, MD, discusses ongoing clinical trials in psoriatic arthritis and data presented at ACR Convergence 2023, as well as upcoming research.
‘We receive almost no training in pain’: Breaking the cycle of chronic pain, depression
SCOTTSDALE, Ariz. — Understanding the relationship between mental and physical distress is essential to breaking the cycle of chronic pain, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
Addressing patient concerns with biologic treatment in hidradenitis suppurativa
Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.
Adults increasingly used complementary health approaches for pain over past 20 years
The overall use of several complementary health approaches, and their use for pain management specifically, rose substantially over the last couple of decades, researchers found.
FDA grants breakthrough therapy designation to opioid with ‘overdose protection’
The FDA has granted breakthrough therapy designation to PF614-MPAR, a “next-generation opioid” designed to limit oral overdose potential, according to a press release from its manufacturer.
Type 2 diabetes drug may reduce colorectal cancer risk
Glucagon-like peptide 1 receptor agonists significantly lowered the risk for colorectal cancer in patients with type 2 diabetes compared with other diabetes medications, according to a research letter in JAMA Oncology.
OK-101 achieves dry eye disease sign, symptom endpoints in phase 2 trial
Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.